For US Healthcare Professionals Only

FIRST AND ONLY

FDA-approved eye drop specifically designed for presbyopia in adults.1,2

Reengineered formulation
of pilocarpine delivered with

pHastTM technology

Rapidly adjusts to physiologic pH*2

*In vitro data. Clinical significance is unknown. The pH range in the bottle is between 3.5 and 5.5.1

Improved

Near and Intermediate Vision

without compromising distance vision1

Primary endpoint was ≥3-line in mesopic, high-contrast, binocular distance-corrected near visual acuity (DCNVA) without losing more than 1 line (5 letters) of corrected distance visual acuity (CDVA) with the same refractive correction at Day 30, Hour 3.1

Change from baseline in photopic, high-contrast, binocular distance-corrected intermediate visual acuity (DCIVA) at Day 30, Hour 3 was a prespecified secondary endpoint.3

Designed to balance

Efficacy, Safety, and Tolerability1,2

Can’t wait to learn more?

Register to be the first to know when VUITY™ becomes available.

INDICATION

VUITY™ (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear.

Rare cases of retinal detachment have been reported with other miotics when used in susceptible patients and those with pre-existing retinal disease. Patients should be advised to seek immediate medical care with sudden onset of vision loss.

VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens.

Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses.

To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface.

ADVERSE REACTIONS

The most common adverse reactions (>5%) reported in clinical trials were headache and conjunctival hyperemia.

Please see full Prescribing Information.

US-PBY-210241

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause

INDICATION

VUITY™ (pilocarpine hydrochloride ophthalmic solution) 1.25% is indicated for the treatment of presbyopia in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VUITY is contraindicated in patients with known hypersensitivity to any ingredient in the formulation.

WARNINGS AND PRECAUTIONS

Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear.

Rare cases of retinal detachment have been reported with other miotics when used in susceptible patients and those with pre-existing retinal disease. Patients should be advised to seek immediate medical care with sudden onset of vision loss.

VUITY is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and lens.

Contact lens wearers should be advised to remove their lenses prior to the instillation of VUITY and to wait 10 minutes after dosing before reinserting their contact lenses.

To prevent eye injury or contamination, care should be taken to avoid touching the dispensing bottle to the eye or to any other surface.

ADVERSE REACTIONS

The most common adverse reactions (>5%) reported in clinical trials were headache and conjunctival hyperemia.

Please see full Prescribing Information.

US-PBY-210241